AUTL
Autolus Therapeutics Ltd - ADR

3,378
Loading...
Loading...
News
all
press releases
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia.
Stocktwits·4mo ago
News Placeholder
More News
News Placeholder
Autolus Therapeutics (AUTL) Gets a Buy from Truist Financial
In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Autolus Therapeutics (AUTL Research Report). The...
TipRanks Financial Blog·1y ago
News Placeholder
China Universal Asset Management Co. Ltd. Invests $105,000 in Autolus Therapeutics plc (NASDAQ:AUTL)
China Universal Asset Management Co. Ltd. bought a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent 13F filing with the...
Zolmax·1y ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 7.5%
Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) dropped 7.5% during trading on Monday . The stock traded as low as $5.90 and last traded at $5.90. Approximately 1,050,329 shares were traded...
Ticker Report·1y ago
News Placeholder
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL
Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action...
Globe Newswire·1y ago
News Placeholder
Autolus Therapeutics (AUTL, $5.68) price exceeded its 50-day Moving Average on April 01, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·1y ago
News Placeholder
Autolus Therapeutics plc (AUTL, $5.68) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024
This indicator may be signaling that AUTL's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Autolus Therapeutics Announces Board Leadership Changes
The latest announcement is out from Autolus Therapeutics Plc (AUTL). John Johnson has stepped down from his role as the chair of Autolus Therapeuti...
TipRanks Financial Blog·1y ago
News Placeholder
Autolus Therapeutics Announces Changes to its Board of Directors
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today...
Globe Newswire·1y ago
News Placeholder
Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by B. Riley Wealth Advisors Inc.
B. Riley Wealth Advisors Inc. decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL Free Report) by 22.7% in the 3rd quarter, according to the company in its most recent filing with...
Zolmax·1y ago

Latest AUTL News

View

Advertisement. Remove ads.

Advertisement. Remove ads.